Effect of survivin siRNA on biological behaviour of breast cancer MCF7 cells

Aliabadi, 2013, Effective response of doxorubicin–sensitive and –resistant breast cancer cells to combinational siRNA therapy, J Contr Release Official: J Contr Release Soc, 172, 219, 10.1016/j.jconrel.2013.08.012 Hong, 2013, S6K1 inhibition enhances tamoxifen–induced cell death in MCE–7 cells through translational inhibition of Mcl–1 and survivin, Cell Biol Toxicol, 29, 273, 10.1007/s10565-013-9253-2 Choi, 2013, Inhibition of S6K1 enhances glucose deprivation–induced cell death via downregulation of anti–apoptotic proteins in MCE–7 breast cancer cells, Biochem Biophys Res Comm, 432, 123, 10.1016/j.bbrc.2013.01.074 Fiskus, 2012, Co–treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells, Breast Cancer Res Treatment, 135, 433, 10.1007/s10549-012-2171-9 Nadin, 2014, Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline–based chemotherapy, Cell Stress & Chaperones, 19, 493, 10.1007/s12192-013-0475-2 Nestal de Moraes, 2013, Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels, European J Cell Biol, 92, 247, 10.1016/j.ejcb.2013.08.001 Muller, 2013, C–terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co–chaperones CHIP and HOP to determine cellular protein folding/degradation balances, Oncogene, 32, 3101, 10.1038/onc.2012.314 Aliabadi, 2013, Polymeric delivery of siRNA for dual silencing of Mcl–1 and P–glycoprotein and apoptosis induction in drug–resistant breast cancer cells, Cancer Gene Ther, 20, 169, 10.1038/cgt.2013.8 Guo, 2012, Research on the expression of Survivin and PTEN in laryngeal squamous cell carcinoma transplanted on the back sides of nude mice treated by gold throat tablets, J Clin Otorhinolaryngol, Head, Neck Surg, 26, 1134 Lu, 2012, Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation, British J Biomed Sci, 69, 143, 10.1080/09674845.2012.12069142 Mobahat, 2014, Survivin as a preferential target for cancer therapy, In J Mol Sci, 15, 2494, 10.3390/ijms15022494 Olsen, 2012, Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors, Mol Ther Nucleic Acids, 1, e30, 10.1038/mtna.2012.19 Ozpolat, 2014, Liposomal siRNA nanocarriers for cancer therapy, Advanced Drug Delivery Rev, 66, 110, 10.1016/j.addr.2013.12.008 Sioud, 2015, RNA interference: mechanisms, technical challenges, and therapeutic opportunities, Methods Molecular Biol, 1218, 1, 10.1007/978-1-4939-1538-5_1 Xu, 2013, Impact of Co–transfection with Livin and survivin shRNA expression vectors on biological behavior of HepG2 cells, Asian Pac J Cancer Prev, 14, 5467, 10.7314/APJCP.2013.14.9.5467 Zhao, 2011, Effect of siRNA–Cox–2 on the growth inhibition and apoptosis of cartilage endplate chondrocytes, Zhonghua Yi Xue Za Zhi, 91, 1031